Literature DB >> 28401522

Classic Hallucinogens and Mystical Experiences: Phenomenology and Neural Correlates.

Frederick S Barrett1, Roland R Griffiths2,3.   

Abstract

This chapter begins with a brief review of descriptions and definitions of mystical-type experiences and the historical connection between classic hallucinogens and mystical experiences. The chapter then explores the empirical literature on experiences with classic hallucinogens in which claims about mystical or religious experiences have been made. A psychometrically validated questionnaire is described for the reliable measurement of mystical-type experiences occasioned by classic hallucinogens. Controlled laboratory studies show that under double-blind conditions that provide significant controls for expectancy bias, psilocybin can occasion complete mystical experiences in the majority of people studied. These effects are dose-dependent, specific to psilocybin compared to placebo or a psychoactive control substance, and have enduring impact on the moods, attitudes, and behaviors of participants as assessed by self-report of participants and ratings by community observers. Other studies suggest that enduring personal meaning in healthy volunteers and therapeutic outcomes in patients, including reduction and cessation of substance abuse behaviors and reduction of anxiety and depression in patients with a life-threatening cancer diagnosis, are related to the occurrence of mystical experiences during drug sessions. The final sections of the chapter draw parallels in human neuroscience research between the neural bases of experiences with classic hallucinogens and the neural bases of meditative practices for which claims of mystical-type experience are sometimes made. From these parallels, a functional neural model of mystical experience is proposed, based on changes in the default mode network of the brain that have been observed after the administration of classic hallucinogens and during meditation practices for which mystical-type claims have been made.

Entities:  

Keywords:  Angular gyrus; Default mode network; Hallucinogens; Inferior parietal lobule; Medial prefrontal cortex; Meditation; Mystical experiences; Neural model; Posterior cingulate; Psilocybin

Mesh:

Substances:

Year:  2018        PMID: 28401522      PMCID: PMC6707356          DOI: 10.1007/7854_2017_474

Source DB:  PubMed          Journal:  Curr Top Behav Neurosci        ISSN: 1866-3370


  35 in total

Review 1.  The acute effects of classic psychedelics on memory in humans.

Authors:  C J Healy
Journal:  Psychopharmacology (Berl)       Date:  2021-01-09       Impact factor: 4.530

2.  Psychedelics for psychological and existential distress in palliative and cancer care.

Authors:  D Rosenbaum; A B Boyle; A M Rosenblum; S Ziai; M R Chasen; MPhil Pall Med
Journal:  Curr Oncol       Date:  2019-08-01       Impact factor: 3.677

Review 3.  Sustained effects of single doses of classical psychedelics in humans.

Authors:  Gitte M Knudsen
Journal:  Neuropsychopharmacology       Date:  2022-06-21       Impact factor: 7.853

4.  Ayahuasca and tobacco smoking cessation: results from an online survey in Brazil.

Authors:  Dimitri Daldegan-Bueno; Lucas Oliveira Maia; Carolina Marcolino Massarentti; Luís Fernando Tófoli
Journal:  Psychopharmacology (Berl)       Date:  2022-02-18       Impact factor: 4.530

Review 5.  The promises and perils of psychedelic pharmacology for psychiatry.

Authors:  Tristan D McClure-Begley; Bryan L Roth
Journal:  Nat Rev Drug Discov       Date:  2022-03-17       Impact factor: 84.694

Review 6.  Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review.

Authors:  Nina Schimmel; Joost J Breeksema; Sanne Y Smith-Apeldoorn; Jolien Veraart; Wim van den Brink; Robert A Schoevers
Journal:  Psychopharmacology (Berl)       Date:  2021-11-23       Impact factor: 4.530

7.  Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences.

Authors:  Theresa M Carbonaro; Matthew W Johnson; Ethan Hurwitz; Roland R Griffiths
Journal:  Psychopharmacology (Berl)       Date:  2017-11-07       Impact factor: 4.530

Review 8.  Combining Psychedelic and Mindfulness Interventions: Synergies to Inform Clinical Practice.

Authors:  Jake E Payne; Richard Chambers; Paul Liknaitzky
Journal:  ACS Pharmacol Transl Sci       Date:  2021-03-16

Review 9.  Ketamine and Serotonergic Psychedelics: Common Mechanisms Underlying the Effects of Rapid-Acting Antidepressants.

Authors:  Bashkim Kadriu; Maximillian Greenwald; Ioline D Henter; Jessica R Gilbert; Christoph Kraus; Lawrence T Park; Carlos A Zarate
Journal:  Int J Neuropsychopharmacol       Date:  2021-01-20       Impact factor: 5.176

10.  Psilocybin-Assisted Group Therapy and Attachment: Observed Reduction in Attachment Anxiety and Influences of Attachment Insecurity on the Psilocybin Experience.

Authors:  Christopher S Stauffer; Brian T Anderson; Kile M Ortigo; Joshua Woolley
Journal:  ACS Pharmacol Transl Sci       Date:  2020-12-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.